FDC,/Geoprumnon1040441.html,CORONATION,SOLOMON,ISLANDS,WHO,Stamps , British Colonies & Territories , Solomon Islands (1893-1978),BRITISH,$1,DR,handicraftstoreagra.com,C260534,1937 $1 DR WHO 1937 BRITISH SOLOMON ISLANDS FDC CORONATION C260534 Stamps British Colonies & Territories Solomon Islands (1893-1978) OFFicial site DR WHO 1937 BRITISH SOLOMON C260534 ISLANDS CORONATION FDC FDC,/Geoprumnon1040441.html,CORONATION,SOLOMON,ISLANDS,WHO,Stamps , British Colonies & Territories , Solomon Islands (1893-1978),BRITISH,$1,DR,handicraftstoreagra.com,C260534,1937 $1 DR WHO 1937 BRITISH SOLOMON ISLANDS FDC CORONATION C260534 Stamps British Colonies & Territories Solomon Islands (1893-1978) OFFicial site DR WHO 1937 BRITISH SOLOMON C260534 ISLANDS CORONATION FDC

OFFicial site DR WHO 1937 BRITISH SOLOMON C260534 ISLANDS Bargain CORONATION FDC

DR WHO 1937 BRITISH SOLOMON ISLANDS FDC CORONATION C260534

$1

DR WHO 1937 BRITISH SOLOMON ISLANDS FDC CORONATION C260534

|||

Item specifics

Seller Notes:
“Please examine pictures closely. Item(s) may be opened on sides, have sealed flaps, tears, folds, scuffs, gouges, or stamp damage. Returns are always accepted if condition is worse than expected.”
Certification:
Uncertified
Grade:
Ungraded
Place of Origin:
United States
Quality:
Used
Type:
Cover


DR WHO 1937 BRITISH SOLOMON ISLANDS FDC CORONATION C260534

Intro Pullout Text Widget

is a leading rheumatology journal from BMJ and EULAR, publishing original research, reviews and recommendations

Impact Factor: 19.103
Citescore: 28.7
All metrics >> 

Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal covering all aspects of rheumatology, which includes the full spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research, including the most important recommendations for the management of various conditions.

ARD is an official journal of EULAR.

Free Furniture Handles Antique furniture handle Handle Antique FB 407 are provided for selected research articles and all #LAC #2 SLASHER PRODUCTS TRAIL SERIES 13.5" 72W 5760m ATV SXS Li. You can keep up with the latest news via Twitter and Facebook.

Listen to the ARD podcast and subscribe in all podcast platforms, including Apple PodcastGoogle PodcastsStitcher and Spotify.

Editor-in-Chief: Professor Josef Smolen, Medical University of Vienna, Austria
Editorial team

ARD is a Plan S compliant Transformative Journal.

Latest Content

Authors

Annals of the Rheumatic Diseases considers unsolicited submissions of a variety of article types, including original research articles (extended and concise reports), viewpoints, and letters to the Editor.
 
The Author Information section provides general guidelines and requirements for specific article types.
 
Information is also provided on editorial policies and open access.

Free Lay Summaries

Are you looking for the latest rheumatology research findings presented in an easily accessible format to share with patients, carers or colleagues?

 

ARD provides free lay summaries for selected research articles and all EULAR recommendations.

 

These aim to clearly explain the results of the research studies as well as any implications for treatment of the specific condition. The summaries are written in plain language in a consistently structured format and checked for accuracy and readability by experts and patient representatives.

 

EULAR Recommendations

The EULAR Standing Committees regularly establish and publish recommendations for the treatment of various rheumatic disorders. Each of these recommendations is developed by a group of specialists in their field.

 

All EULAR recommendations are free to access

 

Each recommendation also has an accompanying Orange Bronco/Levant pattern tolex 34" WIDTH (per yd), which is also free to access.

Video Abstract

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE

To cite: Vital EM, Merrill JT, Morand EF, et al. Ann Rheum Dis. doi: 10.1136/annrheumdis-2021-221425

Read the full article here: link
Objective: To characterise the efficacy and safety of anifrolumab in patients with systemic lupus erythematosus (SLE) according to interferon gene signature (IFNGS), demographic and clinical subgroups.

Conclusions: Overall, this study supports the consistent efficacy and safety of anifrolumab across a range of patients with moderate-to-severe SLE. In a few subgroups, small sample sizes limited conclusions from being drawn regarding the treatment benefit with
anifrolumab.

Podcasts